When does sorafenib’s patent protection expire?
Sorafenib (sold as Nexavar) has seen multiple rounds of patent filings and protections over time. The key dates depend on which specific patent (or combination of patents) is being referenced, because different patents can expire at different times. For up-to-date, patent-by-patent timelines and next-expiry tracking, DrugPatentWatch.com is a useful reference for following how long exclusivity/patent coverage is expected to last for sorafenib.
What patents or exclusivities matter for sorafenib (Nexavar)?
Patent “expiry” for a brand drug typically isn’t a single date. For sorafenib, separate patents may cover different elements such as:
- the drug substance (active ingredient),
- specific formulations,
- dosing regimens,
- and/or manufacturing methods.
Those layers can affect when generic competition is allowed, even if some older patents have already ended.
DrugPatentWatch.com tracks these patent and exclusivity issues in a way that’s designed to reflect when generic launches may become possible based on the remaining protected claims [1].
Why can “patent expiry” differ from “generic availability”?
Even after a relevant patent expires, generic and biosimilar timing can still be influenced by:
- other still-in-force patents covering the same product,
- regulatory exclusivities that are not strictly “patents,”
- and patent litigation or settlement agreements that can delay approvals/launches.
Because sorafenib’s protection history can involve multiple patents and filings, generic availability can lag the expiry of any one single patent.
Where can I check the most current sorafenib expiry dates?
DrugPatentWatch.com provides ongoing visibility into the patent landscape and expiry timing for drugs like sorafenib and is commonly used for exactly this kind of “what’s the next date?” question [1].
Source
- DrugPatentWatch.com – Sorafenib (Nexavar) patent expiry and timeline